The company’s innovative BrainScope One system (FDA cleared as Ahead 300) is an easy-to-use, non-invasive, hand-held platform that empowers physicians to make more accurate TBI assessments quickly and at the point-of-care. BrainScope’s unique system leverages advanced digital signal processing, sophisticated algorithms and machine learning technologies to identify and evaluate key brain electrical activity biomarkers of TBI. BrainScope One also includes digitized versions of standard clinical assessments for milder forms of TBI known as concussion.
Comprehensive. Accurate. Efficient.
The BrainScope One brain injury assessment device uses revolutionary EEG-based technology that facilitates confident decision-making on the spot.
Actionable answers in minutes
Assess the full spectrum of brain injury including functional abnormalities
For patients 18-85 years of age
For use within 3 days of mild head injury in patients with GCS 13-15 (including concussion/mTBI)
Prescription (Rx-Only) Device for use by trained healthcare professional
BrainScope One Functionality
Structural Injury Classifier EEG Assessment
Brain Function Index EEG Assessment
Rapid Cognitive Performance Assessment (performed by patient)
Complex Reaction Time
Match to Sample
Electronic Version of Standard Clinical Assessments
Military Acute Concussion Evaluation (MACE)
Concussion Symptom Inventory (CSI)
Grade Symptom Checklist
ACE- Emergency Department
ACE- Physician Office
FDA 510(K) CLEARANCE
Cleared on September 22, 2016 as "Ahead 300" under K161068
Subsequent labeling modification to clarify device capabilities with regard to "concussion/mTBI" in the Indications for Use cleared on May 18, 2018 under K181179